DBL™ Cisplatin Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

dbl™ cisplatin

pfizer new zealand limited - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: mannitol sodium chloride water for injection - dbl cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, e.g. radiotherapy or surgery.

Cisplatin (Rex) Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

cisplatin (rex)

rex medical ltd - cisplatin 1 mg/ml - solution for injection - 1 mg/ml - active: cisplatin 1 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, eg radiotherapy or surgery.

GENVOYA elvitegravir (150mg), cobicistat (150mg), emtricitabine (200mg) and tenofovir alafenamide (as fumarate) (10mg) fixed dose combination tablets Australia - Inggris - Department of Health (Therapeutic Goods Administration)

genvoya elvitegravir (150mg), cobicistat (150mg), emtricitabine (200mg) and tenofovir alafenamide (as fumarate) (10mg) fixed dose combination tablets

gilead sciences pty ltd - tenofovir alafenamide fumarate, quantity: 11.2 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; microcrystalline cellulose; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - genvoya is indicated as a single tablet regimen for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatment?na?ve; or virologically suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see 5.1 pharmacodynamic properties, clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of genvoya. genvoya is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

PREZCOBIX darunavir/cobicistat 800 mg/150 mg film coated tablet bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

prezcobix darunavir/cobicistat 800 mg/150 mg film coated tablet bottle

janssen-cilag pty ltd - darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - prezcobix, a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of adult patients with human immunodeficiency virus- 1 (hiv-1) infection in:,- antiretroviral treatment-naive patients,- antiretroviral treatment-experienced patients with no darunavir resistance associated mutations and who have plasma hiv-1 rna <100,000 copies/ml,- antiretroviral treatment-experienced but hiv protease inhibitor-naive patients for whom hiv-1 genotype testing is unavailable (see section 4.2 dose and method of administration)

TYBOST 150 mg cobicistat tablets, bottle Australia - Inggris - Department of Health (Therapeutic Goods Administration)

tybost 150 mg cobicistat tablets, bottle

gilead sciences pty ltd - cobicistat, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - tybost is indicated as a pharmacokinetic enhancer of appropriate hiv-1 protease inhibitors in adults (see dosage and administration).

CISPLATIN INJECTION BP SOLUTION Kanada - Inggris - Health Canada

cisplatin injection bp solution

pfizer canada ulc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

CISPLATIN INJECTION, BP SOLUTION Kanada - Inggris - Health Canada

cisplatin injection, bp solution

accord healthcare inc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

CISPLATIN INJECTION BP SOLUTION Kanada - Inggris - Health Canada

cisplatin injection bp solution

sandoz canada incorporated - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

CISPLATIN INJECTION SOLUTION Kanada - Inggris - Health Canada

cisplatin injection solution

strides pharma canada inc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

CISPLATIN INJECTION, MYLAN STD. SOLUTION Kanada - Inggris - Health Canada

cisplatin injection, mylan std. solution

mylan pharmaceuticals ulc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents